AURUMETRICS

HEALTHCARE INTELLIGENCE

Why APAC Evidence Generation Is Falling Behind

The structural delays costing pharmaceutical organizations 18+ months in regional RWE delivery



Real-World Evidence | Medical Affairs | APAC Strategy

Evidence generation in APAC is structurally broken

18+
months average delay
from protocol to publication

67%
of APAC RWE studies miss
regulatory submission windows

3.2x
longer cycle times vs.
US/EU evidence programs

The delay isn't scientific. It's operational.

- Fragmented data partnerships across 12+ APAC markets
- No standardized protocol-to-output infrastructure
- Manual coordination between Medical Affairs, HEOR, and vendors
- Regulatory heterogeneity treated as blockers, not design inputs
- Evidence plans disconnected from market access timelines

> "Organizations are solving a systems problem with project-level thinking."

From fragmented projects to connected evidence infrastructure

01 **DESIGN**
Regulatory-aware protocol architecture that embeds market access from day one

02 **CONNECT**
Unified data partnerships across APAC with standardized governance

03 **GENERATE**
Accelerated evidence production through operational infrastructure

04 **DELIVER**
Synchronized output aligned to submission and launch timelines

What an integrated evidence engine actually looks like

- End-to-end RWE program design aligned to APAC regulatory landscapes
- Pre-built data source connectivity across 12+ markets
- Automated protocol-to-output workflows reducing cycle time by 40%
- Integrated Medical Affairs and Market Access evidence planning
- Real-time program visibility for regional and global stakeholders
- Scalable infrastructure that compounds with each new study

The cost of waiting is compounding

Delayed market access

Every month of evidence delay = lost formulary positioning and competitive ground in key APAC markets

Regulatory risk

Incomplete or late evidence packages trigger additional requirements, extending timelines by 6-12 months

Strategic misalignment

Disconnected evidence and commercial planning creates organizational friction at scale

"The organizations that build evidence infrastructure now will define APAC market leadership for the next decade."

Ready to accelerate your APAC evidence strategy?

Aurumetrics partners with pharmaceutical organizations to design, build, and operate integrated evidence infrastructure across APAC.

- Schedule an evidence infrastructure assessment
- Request the full APAC RWE landscape report
- Connect with our Medical Affairs team

aurumetrics.com

The challenge is no longer whether healthcare data exists.

It is whether the right evidence can be generated fast enough?

Yes, it can.

Aurumetrics supports pharmaceutical and life sciences teams with real-world data intelligence, strategic commercial insight and evidence generation.

GLOBAL MARKET FOOTPRINT

APAC-focused with evidence and data partnerships spanning:

China • Australia • Japan • South Korea • Taiwan • New Zealand

Additional support across the UK, EU, US, and other global markets on an ad hoc basis.

CAPABILITIES

- Sourcing & Integrating Real-World Data Globally
- Advancing Analytical Solutions
- Delivering Strategic Data Insights & Advisory
- Building Powerful Data Collaborations

Claims • EMR • Registry • GP • Lab • Genomics • Linked Data

---

team@aurumetrics.com
www.aurumetrics.com

AURUMETRICS